Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]

Shuja, Syed Hasan; Eqbal, Farea; Rehman, Hafsa

doi:10.2147/dddt.s341223

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 In India, saroglitazar magnesium (Lipaglyn), approved for the treatment of T2D and dyslipidemia, has shown promising results in clinical trials evaluating its therapeutic role in NASH. 10 Saroglitazar is a non-thiazolidinedione and non-fibric acid derivative that acts as a dual regulator of lipid and glucose metabolism by activating PPARα/γ. It has insulin-sensitizing effects by activating PPARγ, which results in a reduction in blood glucose.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Study to Evaluate the Efficacy of Saroglitazar in Non-Alcoholic Steatohepatitis Induced by High Fructose Diet Rat Model

T.,

S.,

Thomas

et al. 2023

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Background Non-alcoholic steatohepatitis (NASH) is a clinical condition with a global prevalence of 25.24%. Peroxisome proliferator-activated receptors (PPAR) have been significantly associated with the pathogenesis of NASH. Aim To evaluate the efficacy of saroglitazar in an animal model of NASH by evaluating the magnitude of changes in liver function tests (LFT) and histopathology. Materials and Methods The baseline parameters of 14 male Sprague–Dawley rats were recorded and then grouped into four groups: treatment groups (high high-dose saroglitazar [HDSG] and low low-dose saroglitazar [LDSG] doses of saroglitazar), normal control, and disease control. Initially, except for the normal control, the other three groups were fed a fructose diet for 5 weeks and then all four groups were fed a standard chow diet for the next 2 weeks during which the two treatment groups were orally gavaged with saroglitazar. Changes in LFT, body weight (BW), lipid profile, oxidative stress, and histopathology were evaluated at different time points. Results A statistically significant reduction was found in the mean serum glutamic-oxaloacetic transaminase (SGOT) ( p = 0.0267) and serum glutamate-pyruvate transaminase (SGPT) ( p = 0.0059) between the groups at the end of treatment. As with BW changes ( p < 0.001), a significant difference was observed between the time points in HDSG and LDSG with respect to all parameters of the lipid profile assessed ( p < 0.05). Amelioration of hepatocellular ballooning and lobular inflammation in histopathology was evident in both treatment groups. Immunohistochemistry revealed loss of cytokeratin CK8/18 in disease control while it was preserved in LDSG and HDSG. Conclusion The study has explicitly illustrated the improvement in the biochemical and pathological changes in the rat model of NASH induced by a high fructose diet.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In India, saroglitazar magnesium (Lipaglyn), approved for the treatment of T2D and dyslipidemia, has shown promising results in clinical trials evaluating its therapeutic role in NASH. 10…”

Section: Introductionmentioning

confidence: 99%

A Study to Evaluate the Efficacy of Saroglitazar in Non-Alcoholic Steatohepatitis Induced by High Fructose Diet Rat Model

T.,

S.,

Thomas

et al. 2023

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

show abstract

“…India approved saroglitazar in 2020 for the treatment of type-2 diabetes mellitus and NASH ( Sarkar et al, 2021 ). However, a phase 2 trial conducted in the United States indicated that the role of saroglitazar in a particular subset of patients with elevated alanine aminotransferase without histological endpoints cannot be recommended ( Kumar, Kulkarni & Jagdish, 2021 ; Shuja, Eqbal & Rehman, 2021 ). Therefore, there is an urgent need to develop pharmacological strategies for the treatment of NAFLD.…”

Section: Introductionmentioning

confidence: 99%

Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation

Yang

Jiang

et al. 2022

PeerJ

View full text Add to dashboard Cite

Background Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease, the incidence of which increases annually. Shugan Xiaozhi (SGXZ) decoction, a composite traditional Chinese medicinal prescription, has been demonstrated to exert a therapeutic effect on NAFLD. In this study, the potential bioactive ingredients and mechanism of SGXZ decoction against NAFLD were explored via network pharmacology, molecular docking, and molecular dynamics simulation. Methods Compounds in SGXZ decoction were identified and collected from the literature, and the corresponding targets were predicted through the Similarity Ensemble Approach database. Potential targets related to NAFLD were searched on DisGeNET and GeneCards databases. The compound–target–disease and protein-protein interaction (PPI) networks were constructed to recognize key compounds and targets. Functional enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) was performed on the targets. Molecular docking was used to further screen the potent active compounds in SGXZ. Finally, molecular dynamics (MD) simulation was applied to verify and validate the binding between the most potent compound and targets. Results A total of 31 active compounds and 220 corresponding targets in SGXZ decoction were collected. Moreover, 1,544 targets of NAFLD were obtained, of which 78 targets intersected with the targets of SGXZ decoction. Key compounds and targets were recognized through the compound–target–disease and PPI network. Multiple biological pathways were annotated, including PI3K-Akt, MAPK, insulin resistance, HIF-1, and tryptophan metabolism. Molecular docking showed that gallic acid, chlorogenic acid and isochlorogenic acid A could combine with the key targets. Molecular dynamics simulations suggested that isochlorogenic acid A might potentially bind directly with RELA, IL-6, VEGFA, and MMP9 in the regulation of PI3K–Akt signaling pathway. Conclusion This study investigated the active substances and key targets of SGXZ decoction in the regulation of multiple-pathways based on network pharmacology and computational approaches, providing a theoretical basis for further pharmacological research into the potential mechanism of SGXZ in NAFLD.

show abstract

Review of current and new drugs for the treatment of metabolic-associated fatty liver disease

Gish,

Fan,

Dossaji

et al. 2024

Hepatol Int

View full text Add to dashboard Cite

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]

Cited by 4 publications

References 4 publications

A Study to Evaluate the Efficacy of Saroglitazar in Non-Alcoholic Steatohepatitis Induced by High Fructose Diet Rat Model

A Study to Evaluate the Efficacy of Saroglitazar in Non-Alcoholic Steatohepatitis Induced by High Fructose Diet Rat Model

Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation

Review of current and new drugs for the treatment of metabolic-associated fatty liver disease

Contact Info

Product

Resources

About